Shigella lipopolysaccharide (Shigella LPS)

Shigella lipopolysaccharide (LPS) is a complex glycolipid that is the major component of the outer membrane of Shigella species. It consists of three domains: lipid A (the endotoxic anchor in the outer membrane), an oligosaccharide core, and the O antigen (a polymer of repeating sugars exposed on the bacterial surface). LPS plays central roles in bacterial virulence, mediating resistance to gastric acid, contributing to membrane integrity, and determining serotype by its structurally variable O antigen. It is the primary pathogen-associated molecular pattern (PAMP) recognized by the host innate immune system, mainly via Toll-like receptor 4 (TLR4), triggering downstream inflammatory signaling. During infection, Shigella actively remodels the structure of its LPS, lowering the inflammatory potential of lipid A to avoid immune detection. The O antigen of Shigella LPS is the principal antigenic determinant used for serotyping and is a key target for vaccine development. Bacteriophages can specifically recognize and bind the highly variable O antigen. Due to its potent inflammatory activity (endotoxemia risk) and variability among serotypes, targeting LPS for therapy poses challenges, but Shigella LPS remains a critical focus for diagnostics, vaccine development, and experimental therapeutics.

Other names

LPS (of Shigella)Shigella LPSShigella lipopolysaccharideShigella O antigenShigella O-polysaccharide

Vaccines: LPS (especially O antigen) used as an immunogen to elicit protective anti-Shigella antibodies. Bacteriophage therapy: Phages (e.g., Sf6) bind O antigen, facilitating bacterial lysis. Modulation of host immune response (agonism of TLR4 pathway; modification of LPS structure decreases immune detection).